The Europe biologics CDMO market is projected to expand from USD 6.93 billion in 2025 to USD 16.26 billion by 2035, growing at a CAGR of 8.9%, fueled by rising biologics demand, outsourcing trends, and increased biopharmaceutical R&D investments across Europe.

Europe Biologics CDMO Market Statical Scope

The market is mainly fueled by the increasing demand for complex biologic drugs such as monoclonal antibodies and vaccines , the growth of biosimilars , and a significant regional trend towards outsourcing R&D and manufacturing to manage costs and leverage specialized technologies.

The market is crucial as it provides specialized infrastructure, regulatory compliance, and scalable capacity needed to produce complex, life-saving drugs. It enables pharmaceutical and biotech companies to safely and efficiently bring advanced therapies, such as monoclonal antibodies , mRNA vaccines, and cell therapies , to the market.

By outsourcing, innovators avoid large capital expenditures on building their own facilities, speeding up research, clinical trials, and commercialization processes. The emergence of advanced therapies, like CAR-T cell treatments, requires custom, small-batch manufacturing. CDMOs provide the adaptable fill-finish platforms and continuous manufacturing capabilities essential to meet this demand.

Europe Biologics CDMO Market Share, By Type, 2025 (%)

• Mammalian - The mammalian cell culture segment is used for complex biologics manufacturing, holding a dominant 68% share because of its high efficiency in producing monoclonal antibodies and therapeutic proteins. Their critical importance comes from unique biological capabilities, strong alignment with regional drug pipelines, and a high dependence on outsourcing.
• Microbial - Microbial expression segment is utilized for cost-effective biologic production, capturing a 32% share due to its effectiveness in simpler recombinant protein manufacturing. They provide highly cost-effective, easily scalable production cycles for key therapeutics compared with mammalian systems.

Europe Biologics CDMO Market Share, By Molecule Type, 2025 (%)

• Monoclonal Antibodies - Monoclonal Antibodies are designed to target specific antigens for therapeutic uses, leading with a 42% share due to the growing demand for targeted therapies in oncology and autoimmune diseases. CDMOs enhance drug pipelines by offering essential manufacturing flexibility, cGMP compliance, and scalable platforms to satisfy high-volume therapeutic requirements.
• Recombinant Proteins - Recombinant proteins produced using recombinant DNA technology account for a 23% share because of their increasing application in chronic disease treatment and therapeutics. They are vital for creating foundational biopharmaceuticals such as insulins, growth hormones, and interferons, while also contributing to the rapid growth of highly competitive biosimilar products in the region.

Europe Biologics CDMO Market Share, By Product Type, 2025 (%)

• Biologics - Biologic drugs created from living organisms for therapeutic purposes hold a dominant 69% market share, driven by strong demand for innovative biologic treatments across various diseases.
• Biosimilars - Highly similar versions of approved biologic drugs that emerge after patent expiration account for 31% of the market share, due to a growing emphasis on cost-effective treatment options. This trend boosts the demand for high-volume manufacturing, lowers healthcare costs to enhance accessibility of therapy, and opens up ongoing opportunities for outsourced clinical development.

Europe Biologics CDMO Market Share, By Indication, 2025 (%)

• Oncology - Biologics utilized in cancer treatment and targeted oncology therapies lead the market with a 37% share, due to the increasing prevalence of cancer and the rising need for precision medicine. This segment dominates the clinical pipeline, necessitates complex handling, and requires significant scalability.
• Auto-Immune Diseases - Biologic therapies aimed at managing immune system disorders represent 26% of the market share, influenced by the high regional prevalence of chronic conditions, intricate manufacturing needs, and a substantial shift towards targeted biologics and biosimilars.

Competitive Landscape

The European biologics CDMO market is driven by significant growth, fueled by the demand for complex therapies. Key players are enhancing their large-scale manufacturing and cell-and-gene therapy capabilities. The market is dominated by multinational companies like Lonza and Thermo Fisher, along with specialized regional firms. Lonza provides comprehensive services ranging from mammalian and microbial expression systems to bioconjugates and mRNA production. They maintain a vast global network with a strong presence in Europe. Thermo Fisher Scientific delivers contract development and commercial manufacturing for biologics, aseptic fill-and-finish, and thorough drug product development through its Patheon services brand. The market has experienced notable M&A activity, including Novo Holdings' purchase of Catalent and Agilent's acquisition of Biovectra, which has increased regional capacity for biologics and gene therapies.

Segments Covered in the Report

By Type

• Mammalian
• Microbial

By Molecule Type

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Hormones
• Others

By Product Type

• Biologics
• Biosimilars

By Indication

• Oncology
• Auto-Immune Diseases
• Infectious Diseases
• Neurology
• Others